Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 9 | 2023 | 477 | 1.620 |
Why?
|
| Head and Neck Neoplasms | 15 | 2022 | 2734 | 1.080 |
Why?
|
| Antineoplastic Agents | 12 | 2016 | 13695 | 0.720 |
Why?
|
| Antibodies, Monoclonal | 7 | 2016 | 9274 | 0.700 |
Why?
|
| Gastrointestinal Diseases | 3 | 2016 | 1170 | 0.670 |
Why?
|
| Ferrosoferric Oxide | 1 | 2020 | 360 | 0.650 |
Why?
|
| Ferric Compounds | 1 | 2020 | 374 | 0.630 |
Why?
|
| Aspartate Aminotransferases | 2 | 2015 | 418 | 0.600 |
Why?
|
| Papillomavirus Infections | 4 | 2023 | 1587 | 0.570 |
Why?
|
| Alanine Transaminase | 2 | 2015 | 592 | 0.550 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2018 | 178 | 0.550 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 7 | 2022 | 1624 | 0.550 |
Why?
|
| Neoplasms | 16 | 2020 | 21683 | 0.540 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 405 | 0.520 |
Why?
|
| Quinazolines | 3 | 2018 | 1356 | 0.510 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 895 | 0.510 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 640 | 0.480 |
Why?
|
| Oxonic Acid | 4 | 2018 | 41 | 0.470 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5221 | 0.470 |
Why?
|
| Tegafur | 4 | 2018 | 49 | 0.470 |
Why?
|
| Deoxycytidine | 1 | 2018 | 826 | 0.470 |
Why?
|
| Radiation Oncology | 2 | 2019 | 555 | 0.470 |
Why?
|
| Alopecia | 1 | 2017 | 382 | 0.440 |
Why?
|
| Cholangiocarcinoma | 1 | 2018 | 516 | 0.430 |
Why?
|
| Proteinuria | 1 | 2015 | 658 | 0.420 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2015 | 5535 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2018 | 11524 | 0.400 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 498 | 0.400 |
Why?
|
| Diphosphonates | 1 | 2014 | 623 | 0.350 |
Why?
|
| Artificial Intelligence | 2 | 2020 | 2214 | 0.350 |
Why?
|
| Tumor Burden | 5 | 2022 | 1915 | 0.340 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2020 | 8949 | 0.330 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 4034 | 0.320 |
Why?
|
| Lung Neoplasms | 6 | 2022 | 13102 | 0.310 |
Why?
|
| Risk | 10 | 2020 | 9687 | 0.310 |
Why?
|
| Indoles | 1 | 2016 | 1839 | 0.310 |
Why?
|
| Liver Diseases | 1 | 2016 | 1253 | 0.310 |
Why?
|
| Pyrimidines | 2 | 2017 | 2942 | 0.310 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 773 | 0.290 |
Why?
|
| Sulfonamides | 1 | 2017 | 1938 | 0.290 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 2038 | 0.280 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2015 | 808 | 0.280 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 1524 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 3508 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2020 | 20129 | 0.250 |
Why?
|
| Drug Combinations | 4 | 2018 | 1959 | 0.250 |
Why?
|
| Brain Neoplasms | 5 | 2024 | 8863 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 2728 | 0.230 |
Why?
|
| Smoking | 1 | 2020 | 8987 | 0.230 |
Why?
|
| Heart Diseases | 1 | 2016 | 2788 | 0.220 |
Why?
|
| Parotid Gland | 2 | 2020 | 168 | 0.220 |
Why?
|
| Algorithms | 9 | 2020 | 13881 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 9959 | 0.210 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 3143 | 0.200 |
Why?
|
| Odds Ratio | 5 | 2016 | 9849 | 0.190 |
Why?
|
| Humans | 57 | 2024 | 744343 | 0.190 |
Why?
|
| Thoracic Cavity | 1 | 2020 | 13 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2020 | 806 | 0.180 |
Why?
|
| Osteoradionecrosis | 1 | 2020 | 49 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4262 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 35421 | 0.180 |
Why?
|
| Mandibular Diseases | 1 | 2020 | 119 | 0.180 |
Why?
|
| Neoplasm Staging | 7 | 2023 | 11031 | 0.170 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2022 | 286 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 3 | 2015 | 2727 | 0.170 |
Why?
|
| Salivary Glands | 1 | 2019 | 229 | 0.160 |
Why?
|
| Ampulla of Vater | 1 | 2018 | 141 | 0.150 |
Why?
|
| Privacy | 1 | 2020 | 239 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 221 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 285 | 0.150 |
Why?
|
| Mitomycin | 1 | 2018 | 259 | 0.150 |
Why?
|
| Pleural Effusion | 1 | 2020 | 338 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 388 | 0.150 |
Why?
|
| Computer Graphics | 1 | 2019 | 361 | 0.150 |
Why?
|
| Organs at Risk | 1 | 2019 | 346 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2017 | 629 | 0.150 |
Why?
|
| Papillomaviridae | 2 | 2020 | 1119 | 0.140 |
Why?
|
| Skin Diseases | 2 | 2015 | 1065 | 0.140 |
Why?
|
| Contrast Media | 2 | 2020 | 5300 | 0.140 |
Why?
|
| Radiometry | 2 | 2019 | 800 | 0.140 |
Why?
|
| Retrospective Studies | 18 | 2024 | 77449 | 0.140 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 408 | 0.140 |
Why?
|
| Gallbladder Neoplasms | 1 | 2018 | 183 | 0.140 |
Why?
|
| Hair Color | 1 | 2017 | 136 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2023 | 1533 | 0.140 |
Why?
|
| Stomatitis | 2 | 2015 | 269 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 841 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 423 | 0.130 |
Why?
|
| Mandible | 1 | 2020 | 740 | 0.130 |
Why?
|
| Indazoles | 1 | 2017 | 289 | 0.130 |
Why?
|
| Antibodies, Blocking | 1 | 2015 | 253 | 0.130 |
Why?
|
| Neck | 1 | 2019 | 697 | 0.130 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 3507 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2023 | 1329 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2023 | 1241 | 0.120 |
Why?
|
| Endocrine System Diseases | 1 | 2016 | 248 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 625 | 0.110 |
Why?
|
| Incidence | 5 | 2023 | 20947 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 648 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 20822 | 0.110 |
Why?
|
| Cisplatin | 1 | 2018 | 1662 | 0.100 |
Why?
|
| Diarrhea | 2 | 2015 | 1348 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2020 | 3327 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2375 | 0.100 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 1415 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2022 | 53288 | 0.090 |
Why?
|
| Female | 21 | 2024 | 380194 | 0.090 |
Why?
|
| Computational Biology | 2 | 2020 | 3521 | 0.090 |
Why?
|
| Neutropenia | 1 | 2016 | 895 | 0.090 |
Why?
|
| Prognosis | 8 | 2023 | 29063 | 0.090 |
Why?
|
| Observer Variation | 2 | 2022 | 2593 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2020 | 10252 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5078 | 0.090 |
Why?
|
| Middle Aged | 17 | 2020 | 213383 | 0.090 |
Why?
|
| Positron-Emission Tomography | 3 | 2021 | 6234 | 0.090 |
Why?
|
| Neutrophils | 1 | 2022 | 3719 | 0.090 |
Why?
|
| Piperidines | 1 | 2018 | 1602 | 0.090 |
Why?
|
| Gastrointestinal Tract | 1 | 2015 | 814 | 0.090 |
Why?
|
| Glioma | 1 | 2024 | 3401 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2023 | 63114 | 0.080 |
Why?
|
| Male | 18 | 2024 | 350118 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15540 | 0.080 |
Why?
|
| Colitis | 1 | 2015 | 1170 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2019 | 3474 | 0.070 |
Why?
|
| Genomics | 2 | 2023 | 5720 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 1372 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 3479 | 0.070 |
Why?
|
| Aged | 13 | 2020 | 163280 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2016 | 2616 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 4851 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 2214 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2020 | 3481 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3798 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2023 | 2715 | 0.060 |
Why?
|
| Receptor, erbB-2 | 1 | 2014 | 2416 | 0.060 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12354 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 6364 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 57776 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2022 | 2617 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2020 | 1180 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2019 | 2879 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4253 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2022 | 3760 | 0.050 |
Why?
|
| ROC Curve | 2 | 2020 | 3527 | 0.050 |
Why?
|
| Adult | 10 | 2020 | 214055 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 2043 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2015 | 4445 | 0.040 |
Why?
|
| Parotid Diseases | 1 | 2019 | 46 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 7913 | 0.040 |
Why?
|
| Xerostomia | 1 | 2019 | 95 | 0.040 |
Why?
|
| Child | 2 | 2024 | 77709 | 0.040 |
Why?
|
| Mediastinum | 1 | 2019 | 267 | 0.040 |
Why?
|
| Age Factors | 1 | 2014 | 18370 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.040 |
Why?
|
| Melanoma | 1 | 2015 | 5510 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
| Young Adult | 5 | 2020 | 56430 | 0.030 |
Why?
|
| Pharynx | 1 | 2019 | 413 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12788 | 0.030 |
Why?
|
| Posture | 1 | 2019 | 958 | 0.030 |
Why?
|
| Glycolysis | 1 | 2019 | 827 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2019 | 1654 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2020 | 1125 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 2886 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 261 | 0.030 |
Why?
|
| Workflow | 1 | 2019 | 847 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2505 | 0.030 |
Why?
|
| Benchmarking | 1 | 2020 | 1042 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 605 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2020 | 7729 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 2016 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 434 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 1578 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 2618 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 975 | 0.030 |
Why?
|
| Vomiting | 1 | 2015 | 636 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 3462 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2020 | 1928 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 6895 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2023 | 4554 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 2924 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 72290 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2015 | 1619 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1941 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 2480 | 0.020 |
Why?
|
| Artifacts | 1 | 2018 | 1904 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7301 | 0.020 |
Why?
|
| Disease Management | 1 | 2020 | 2459 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 3508 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2023 | 23338 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8642 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3586 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 29786 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2019 | 40561 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 3036 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9438 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13284 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 9856 | 0.010 |
Why?
|
| Adolescent | 2 | 2020 | 85781 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 19905 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40075 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 23403 | 0.010 |
Why?
|
| United States | 1 | 2017 | 69872 | 0.010 |
Why?
|
Concepts
(203)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(21)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_